FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO	DVAL					
OMB Number:	3235-0287					
Estimated average burd	len					
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>KIDRON NADAV</u>					2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. ORMP]									-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner					
(Last) 12 ELIEZ	•	irst) (ADOL ST.	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/18/2015										Offic belov	,	Other (below) t and CEO		
(Street) JERUSALEM L3 9359038 (City) (State) (Zip)					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indi Line) X					
		Tabl	le I - Nor	n-Deriva	ative	Sec	uritie	es Acc	quired,	Dis	osed o	f, o	r Ben	efic	ially	Owne	ed			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)					4 and Second Ben Owr		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
								Code	v	Amount		(A) or (D)	Pri	се	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common	03/18	/2015		P		500		A	\$	3.78	954,448			D						
Common	/2015				P		500		A	\$3.8		954,948			D					
Common	/2015				P		400		A	\$3.95		955,348			D					
Common Stock 03/19/									P		1,100		A	\$3.92		956,448		D		
Common Stock 03/19/						/2015			P		100		A		\$4	956,548			D	
		Та	able II - D								sed of, onvertib					wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deem Execution if any (Month/Da	Date,	I. Fransaction Code (Instr. 3)		n of E		6. Date E Expiratio (Month/D	n Date	•	Am Sec Un Dec	Title and nount of curities derlying rivative curity (Ir d 4)		Der Sec (Ins	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Ov Fo Di or (I)	vnership orm: rect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Coo		Code	,					Expiration Date	Numb of Title Share										

Explanation of Responses:

/s/ Nadav Kidron

03/20/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).